Suomen Terveystalo Oy — Clinical Trial Site

43 Registered trials

13 Currently recruiting

Organisation

Suomen Terveystalo Oy

Location

Helsinki, Finland

Identifier

ORG-100045396

Address

Valimotie 21, 00380, Finland

Departments

2krs. H216
4504: Internal Medicine
6901: General Practice
Clinical Research
Clinical Trials
Department of Clinical Trials
Helsinki Sleep Clinic
Helsinki Sleep Clinic Terveystalo Healthcare
Ihotaudit ja allergologia
Jyväskylä
N/A
NA
Psychiatry
Suomen Terveystalo Oy
Terveystalo Biobank and Clinical Research
Terveystalo Helsinki Uniklinikka
Terveystalo Clinical Research
Terveystalo Helsinki
Terveystalo Helsinki Sleep Clinic
Terveystalo Oulu
Terveystalo Pulssi
Terveystalo Ruoholahti
Terveystalo Ruoholahti Helsinki
Terveystalo Sleep Clinic
Terveystalo Tampere
Terveystalo Turku
Turku

Clinical trials at this site (43)

Search interface

Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised

2022-501535-16-00 Atopic Dermatitis (AD) 5
An Open-label Study of Azetukalner in Major Depressive Disorder Recruiting

2025-523618-10-00 Major Depressive Disorder 5 2026-06-04
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting

2025-523202-32-00 Major Depressive Disorder 5 2026-02-26
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to assess the efficacy and safety of ITI-1284 as monotherapy treatment in patients with Generalized Anxiety Disorder Recruiting

2024-516684-82-00 Generalized Anxiety Disorder 4 2025-07-21
A study to test the safety and tolerability of Lu AH69593 in adults that are healthy or have narcolepsy. Recruiting

2024-511073-29-00 Narcolepsy 3 2025-06-13
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting

2023-506150-21-00 Celiac Disease 4 2024-05-29
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
A Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease Ended

2024-517081-42-00 Celiac Disease 4 2025-08-15
AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI… Ended

2023-505601-16-00 Chronic Migraine 5 2025-04-22
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Prurigo Nodularis 5 2024-11-01
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended

2023-508462-15-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 10 2023-04-27
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Atopic Dermatitis 5 2019-01-02
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended

2025-521107-42-00 Alzheimer's Disease 4 2025-11-25
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2024-511998-30-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 5 2024-10-18